761 - Second-line docetaxel (D) in metastatic gastric cancer (mGC)

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer Agents
Gastric Cancer
Therapy
Biological Therapy
Presenter Chiara Caparello
Authors C. Caparello1, M. Lencioni1, E. Vasile2, S. Caponi3, S. Santi4, M.G. Fabrini5, L. Ginocchi1, M. Lucchesi3, S. Ricci1, A. Falcone6
  • 1Oncologia, Trapianti E Nuove Tecnologie In Medicina, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, 56126 - Pisa/IT
  • 2Oncology, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, 56126 - Pisa/IT
  • 3Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, 56126 - Pisa/IT
  • 4Department Of Gastroenterology, Esophageal Surgery Unit, Tuscany Regional Referral Center for the Diagnosis and Treatment of Esophageal Disease, Pisa, Italy, Pisa/IT
  • 5Division Of Radiation Oncology, S. Chiara Pisa Hospital, Pisa, Italy, Pisa/IT
  • 6Dept. Of Oncology-presidio Ospedaliero, Polo Oncologico - Azienda Ospedaliero-Universitaria Pisana - Istituto Toscano Tumori, 56126 - Pisa/IT

Abstract

Background

Although second-line chemotherapy with irinotecan or docetaxel seemed to confer an improvement in overall survival over best supportive care, at today no standard second-line chemotherapy regimen is approved in MGC. Methods: The objective of our retrospective analysis was to evaluate the activity of a second-line taxane-based treatment in MGC patients (pts).

Results

A total of forty-eight pts (M/F 40/8; ECOG PS at second-line treatment 0/1/2: 23/22/3) were included in the study; median age 67 years (range 38-86). All pts received a first-line fluoropyrimidine-based chemotherapy; 42 in combination with platinum compounds (9 received a triplet with anthracyclines and 2 with Herceptin) and 6 in monochemotherapy. 46 pts were evaluable for analysis: 37 pts received a docetaxel monochemotherapy (16 weekly, 5 biweekly and 16 three-weekly schedule), 10 a combination of docetaxel with fluorouracil, 1 with cisplatin. Grade 3 or 4 toxicities included: anemia 3 pts, neutropenia 6 pts, diarrhea 1 patient, fatigue, vomiting and neurotoxicity 1 patient each, stomatitis 2 pts; 13 pts needed a delay of treatment and 5 a reduction of doses. Among 46 evaluable pts 7 (15.2%) experienced a partial response, 13(28.3%) a stable disease, 26(56.5%) a progression of disease. 24 pts received a third-line chemotherapy, 21 of these an irinotecan-based treatment. Median progression-free survival was 4.3 months and median overall survival was 8.6 months from the start of second-line treatment. No significant differences were found in mPFS, RR and toxicity profile between different treatment schedules. mPFS seemed to be longer in patients with PS 0 than in patients with PS 1 or 2 (5.4 months versus 2.1 and 0.95 respectively; p = 0.046). No difference in mPFS was detected according to RR at first-line therapy.

Conclusions

Docetaxel in MGC second-line setting seems to have an encouraging activity with an acceptable toxicity profile.

Disclosure

All authors have declared no conflicts of interest.